Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03551691 · ClinicalTrials.gov registry record · Phase 2
Proton Pump Inhibitors (PPI) and Fat Absorption in Cystic Fibrosis (CF) and Exocrine Pancreatic Insufficiency (EPI)
A Phase 2 study, sponsored by Children's Hospital of Philadelphia.
- Completed
- Registry status
- Phase 2
- Development phase
- 19
- Enrollment target
NCT03551691 is a Phase 2 study that has completed, run by Children's Hospital of Philadelphia. The registered enrollment target is 19 participants.
The verdict
NCT03551691, a Phase 2 study, has completed, sponsored by Children's Hospital of Philadelphia.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 19 participants
- Enrollment target
Study Summary
This is a clinical trial with a cross over design investigating the effect of the proton pump inhibitor omeprazole on fat malabsorption in subjects with cystic fibrosis and pancreatic insufficiency. Participants will be randomized to receive either omeprazole or placebo for 28 days, then cross over and receive omeprazole or placebo for another 28 days. Markers of fat absorption will be measured after each treatment course.
Interventions
- DRUG Placebo oral capsule
- DRUG Omeprazole 20mg Capsule
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19 participants |
| Start Date | 2018-08-07 |
| Est. Completion | 2022-11-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03551691
The ClinicalTrials.gov registry entry for NCT03551691 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 19 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Children's Hospital of Philadelphia, which has 431 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo oral capsule is the first listed.
NCT03551691 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03551691 about?
NCT03551691 is a clinical study titled "Proton Pump Inhibitors (PPI) and Fat Absorption in Cystic Fibrosis (CF) and Exocrine Pancreatic Insufficiency (EPI)". This is a clinical trial with a cross over design investigating the effect of the proton pump inhibitor omeprazole on fat malabsorption in subjects with cystic fibrosis and pancreatic insufficiency. Participants will be randomized to receive either omeprazole or placebo for 28 days, then cross over ...
What is the current status of trial NCT03551691?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 19 participants. The study started on 2018-08-07. Estimated completion is 2022-11-02.
What interventions are being tested in trial NCT03551691?
The interventions under investigation include: Placebo oral capsule (DRUG), Omeprazole 20mg Capsule (DRUG).
Who is sponsoring clinical trial NCT03551691?
This trial is sponsored by Children's Hospital of Philadelphia, which has 431 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.